



MEDIA RELEASE

Kuala Lumpur / Singapore, 26 May 2026

## IHH Healthcare delivers sustained growth in Q1 2026

Diversified footprint provided resilience and growth

“Our steady growth in Q1 2026 is on the back of strong performances in Malaysia, Türkiye & Europe and India. This showcases the unique strength of IHH’s diversified footprint even as the industry navigates heightened volatility globally. Our continued strategic execution of organisation-wide transformation initiatives will empower us to build a future-ready IHH and deliver our target of double-digit ROE by 2028.”

-- Dr Prem Kumar Nair, Group Chief Executive Officer, IHH Healthcare

### GROUP RESULTS – Q1 2026 FINANCIAL SUMMARY

<i>Financials (RM)</i>	Reported Q1 2026 key metrics (YoY)		<u>Core</u> <sup>1</sup> Q1 2026 key metrics (YoY)	
	Q1 2026	YoY (%)	Q1 2026	YoY (%)
Revenue	RM6.6b	+4%	RM6.5b	+16%*
EBITDA	RM1.4b	+7%	RM1.4b	+16%*
PATMI (ex EI)	RM459m	+8%	RM545m	+5%
PATMI	RM528m	+3%	RM541m	+4%

\*On constant currency basis

#### Q1 2026: Steady growth on overall strength from diversified and resilient portfolio

- **Core** revenue, on a constant currency basis, was up 16% YoY (RM6.5b) while **Core PATMI (ex EI)** was up 5% YoY (RM545m) respectively. Higher inpatient and daycase volumes, and taking on more complex cases all contributed to growth.
- At a country level, **Malaysia, Türkiye/Europe and India all had strong performances:**
  - Malaysia continued to increase medical tourism share and improve revenue intensity, while expanding its capital-efficient daycare model.
  - Türkiye and Europe delivered strong growth across all key metrics, experiencing strong local and foreign demand despite a full month of Eid impact.

<sup>1</sup> Excluding effects of application of MFRS129 accounting



- India continues to benefit from Fortis Healthcare and Gleneagles India integration from their [maintenance services agreement](#) (MSA) as well as organic growth.
- Singapore is facing structural shifts towards public healthcare utilisation. Clear measures in place to steady performance, with **recovery expected in H2 2026**:
  - Refined patient targeting: Mount Elizabeth to focus on high-value, high-intensity care; Gleneagles and Parkway East to drive volumes; daycare/ ambulatory care expansion to support out-of-hospital strategy
  - Overall volume growth: More tie-ups with corporates; more competitive insurer packages; grow medical tourism beyond traditional catchments
  - Strong cost controls across the board
- **Reported revenue** was up 4% YoY (RM6.6b); **reported PATMI** was up 3% YoY (RM528m) as **strength of Group's diversified portfolio** mitigated translation impact from a stronger Ringgit.

## GROUP OUTLOOK

- IHH is on a multi-year transformation journey to future-proof its business, accelerate growth and drive profitability; targeting double-digit ROE by 2028:
  - In May, it announced that it is [partnering Oracle](#) to unify its finance, human resources and supply chain systems into a single AI-enabled cloud platform to boost productivity, cost efficiency and patient-centred care.
- Amid rising demand, IHH remains confident in its growth path. Its 2026 focus areas are:
  - **Malaysia**: Continue to grow daycare and medical tourism segments, strengthen payor partnerships and conduct brownfield expansion selectively.
  - **Singapore**: Strengthen payor partnerships, grow medical tourism from non-traditional markets, sustain quaternary excellence via Mount Elizabeth and optimise and scale network effects from presence across continuum.
  - **India**: Fortis and Gleneagles MSA will continue to drive scale and leverage; will also accelerate strategic brownfield expansion and M&A.
  - **Türkiye and Europe**: Acibadem will focus on maintaining market leadership while staying capital-light and driving operational resilience.
- IHH also remains prudent on its capital management while navigating through global volatilities and uncertainties.

+++



## **ABOUT IHH HEALTHCARE (“IHH”)**

IHH is a leading multinational healthcare provider shaping the future of care. Driven by our aspiration to Care. For Good., we unite medical excellence and innovation, pushing boundaries through our trusted brands such as Acibadem, Gleneagles, Fortis, Island, Mount Elizabeth, Pantai, Parkway and Prince Court.

Across 10 countries, including Malaysia, Singapore, Türkiye, India and Greater China, our 76,000-strong team delivers world-class excellence every day, within and beyond our 190 healthcare facilities, including 89 hospitals. Our comprehensive services span the full healthcare continuum, from primary and ambulatory to quaternary care, complemented by diagnostics, imaging, rehabilitation, telehealth and home care.

In partnership with our stakeholders, IHH is advancing value-based care, building a sustainable healthcare ecosystem and creating meaningful impact, as we work towards our vision to become the world’s most trusted healthcare services network.

[www.ihhhealthcare.com](http://www.ihhhealthcare.com)

For more information or to speak to an IHH spokesperson, please contact:

Kelvin Chong

Investor Relations,

IHH Healthcare

t. +65 9489 5357

e. [kelvin.chong@ihhhealthcare.com](mailto:kelvin.chong@ihhhealthcare.com)

Jeremy Fong

Investor Relations,

IHH Healthcare

t. +65 8127 3352

e. [jeremy.fong@ihhhealthcare.com](mailto:jeremy.fong@ihhhealthcare.com)